NCT07366268Not yet recruiting
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis
Evaluation of Topical Apremilast Nanoparticles in the Treatment of Plaque Psoriasis: Clinical, Histopathological and Immunohistochemical Study
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This study is a comparative randomized clinical trial evaluating the efficacy and safety of topical apremilast nanoemulsion 0.3% in the treatment of localized mild to moderate plaque psoriasis.Clinical efficacy will be assessed using TES score, Physician Global Assessment (PGA), dermoscopy, and patient satisfaction, while safety is monitored through adverse effect reporting. In addition, histopathological and immunohistochemical evaluation of PDE4 expression will be performed before and after treatment to assess tissue-level responses. The study aims to determine whether topical apremilast nano-formulation, alone or combined with corticosteroids, offers an effective and safer alternative to conventional topical therapy, with improved local efficacy and reduced corticosteroid-related adverse effects.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 10 Jan 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- Assiut University
- Diseases
- Psoriasis
- NCT number
- NCT07366268
What you commit to
- Study type: Interventional
- Planned participants: 36
- From 1 May 2026 to the primary completion date, 31 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of phototherapy or systemic treatment in the previous 12 weeks, topical psoriasis treatment within the last 4 weeks.
Other illness
- Renal, hepatic disease, cardiovascular, Immunosuppressive therapy, endocrine and blood disease or mental illness.
Other
- Pregnancy, breast-feeding or women planning to become pregnant within 3 months.
- Psoriasis exceeding 10% of body surface area or other severe types of psoriasis requiring systemic treatment.
Who the study is looking for
- Age: ≥18 years.
- Pattern: Patients with chronic plaque psoriasis not exceeding 10% of the body surface area.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.